• Home
  • /
  • Uncategorized
  • /
  • Phase 3 DECISION Trial Investigating the Use of Nexavar® (sorafenib) Demonstrated Significant Improvement in Progression-Free Survival in Patients with Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Phase 3 DECISION Trial Investigating the Use of Nexavar® (sorafenib) Demonstrated Significant Improvement in Progression-Free Survival in Patients with Radioactive Iodine-Refractory Differentiated Thyroid Cancer

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., June 2, 2013 /PRNewswire/ – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced positive results from the Phase 3 DECISION trial investigating the use of Nexavar® (sorafenib) tablets in patients with l